A Safety Study of SGN-CD48A in Patients With Multiple Myeloma

Study Overview
=================
Brief Summary
-----------------
This study will test the safety and activity of SGN-CD48A in patients with multiple myeloma. SGN-CD48A will be given on Days 1, 8, and 15 of a 28-day cycle. Prior to protocol amendment 2, SGN-CD48A was given every 3 weeks.

Detailed Description
-----------------
This study is designed to evaluate the safety, tolerability, and antitumor activity of SGN-CD48A in patients with relapsed or refractory multiple myeloma. This study will be conducted in 2 parts: Dose escalation: This part will evaluate increasing doses of SGN-CD48A to identify the maximum tolerated dose. The first group of patients enrolled on the study will receive the lowest dose of SGN-CD48A. Once this dose is shown to be safe, a second group of patients will be enrolled at the next higher dose. Patients will continue to be enrolled in groups receiving increasing doses until the maximum tolerated dose level is reached. Patients can only be enrolled into a higher dose level once the lower doses have been demonstrated safe. Dose escalation will be conducted using a modified toxicity probability interval (mTPI) study design. Dose expansion: This part will further evaluate the safety, tolerability, and antitumor activity of up to 2 dose levels of SGN-CD48A shown to be safe in the first part of the trial.

Official Title
-----------------
A Phase 1 Study of SGN-CD48A in Patients With Relapsed or Refractory Multiple Myeloma

Conditions
-----------------
Multiple Myeloma

Intervention / Treatment
-----------------
* Drug: SGN-CD48A


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Diagnosis of MM requiring systemic therapy (per the International Myeloma Working Group [IMWG]) Patients must not have other therapeutic options known to provide clinical benefit in MM available to them. Prior lines of therapy must include at least a proteasome inhibitor, an immunomodulatory drug, and an anti-CD38 antibody. Measureable disease, as defined by at least one of the following: serum M protein 0.5 g/dL or higher, urine M protein 200 mg/24 hour or higher, and serum immunoglobulin free light chain 10 mg/dL or higher and abnormal serum immunoglobulin kappa lambda free light chain ratio Adequate hematologic, renal, and hepatic function Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1 Life expectancy greater than 3 months A negative pregnancy test (for females of childbearing potential) Patients must provide written consent Exclusion Criteria: Pre-existing peripheral neuropathy Grade 2 or higher History of malignancy other than MM within the past 3 years Active cerebral/meningeal disease related to the underlying malignancy Uncontrolled Grade 3 or higher infection Known to be positive for HIV or hepatitis B, or known to have active hepatitis C infection Previous allogeneic stem cell transplant History of cerebral vascular event, unstable angina, myocardial infarction, or cardiac symptoms consistent with congestive heart failure within the last 6 months Treatment with any known P-gp inducers/inhibitors or strong CYP3A inhibitors within 14 days prior to the first dose of study drug Prior antitumor therapy that is not completed at least 4 weeks prior to first dose of study drug, or at least 2 weeks if progressing. Prior CAR T-cell therapy must be completed 8 weeks before first dose of study drug. Females who are pregnant or breastfeeding

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Intervention Model: Single Group Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: SGN-CD48A<br>SGN-CD48A | Drug: SGN-CD48A<br>* Intravenous (IV) infusion on days 1, 8, and 15 of a 28-day cycle<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Type, incidence, severity, seriousness, and relatedness of adverse events |  | Through 1 month following last dose | 
| Incidence of laboratory abnormalities |  | Through 1 month following last dose | 
| Incidence of dose limiting toxicity |  | Through 3 weeks following first dose | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Objective response rate | The proportion of patients with stringent complete response, complete response, very good partial response, or partial response per investigator | Through 1 month following last dose | 
| Complete response rate | The proportion of patients with stringent complete response or complete response per investigator | Through 1 month following last dose | 
| Duration of objective response |  | Up to approximately 3 years | 
| Duration of complete response |  | Up to approximately 3 years | 
| Progression-free survival |  | Up to approximately 3 years | 
| Overall survival |  | Up to approximately 3 years | 
| Blood concentrations of SGN-CD48A and metabolites |  | Through 1 month following last dose | 
| Incidence of antitherapeutic antibodies |  | Through 1 month following last dose | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Multiple myeloma, Antibody-drug conjugate